Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Old Mutual shares fall as FY guidance range disappoints

(Sharecast News) - Old Mutual shares were trading lower on Wednesday after the Africa-focused financial services firm gave a wide guidance range for its 2024 results, pointing to annual profit growth of anywhere between 4% and 24%. The company, which provides investment, savings, insurance and banking services, said adjusted headline earnings would be between ZAR6.10bn-7.27bn (£256m-308m) for 2024, up from ZAR5.86bn in 2023.

Headline earnings per share growth is expected to be somewhere between 13% and 33% higher from the previous year's ZAR165.5 cents, equating to a range of 187.0-220.1 cents.

The company said results from operations were driven by strong performances at the Old Mutual Insure, Wealth Management and Old Mutual Investments divisions, partially offset by lower life profits in Personal Finance as well as investments in OM Bank.

Meanwhile, adjusted earnings growth was helped by increased shareholder investment returns, while 2023's headline bottom line was held back by one-off hedging losses.

Old Mutual is due to release its full-year results on 18 March. However, shares were down 5.7% at 49.3p by 1415 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.